A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis

S.H. Omland; A. Habicht; P. Damsbo; J. Wilms; B. Johansen; R. Gniadecki

doi:10.1111/jdv.14128

A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.14128 ◽

2017 ◽

Vol 31 (7) ◽

pp. 1161-1167 ◽

Cited By ~ 8

Author(s):

S.H. Omland ◽

A. Habicht ◽

P. Damsbo ◽

J. Wilms ◽

B. Johansen ◽

...

Keyword(s):

Phospholipase A2 ◽

Dose Escalation ◽

Plaque Psoriasis ◽

Cytosolic Phospholipase A2 ◽

Study Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Cytosolic Phospholipase ◽

Phase 0

Download Full-text

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Journal of Dermatological Treatment ◽

10.3109/09546634.2015.1115819 ◽

2016 ◽

Vol 27 (4) ◽

pp. 332-338 ◽

Cited By ~ 32

Author(s):

Robert Bissonnette ◽

Monica Luchi ◽

Rosanne Fidelus-Gort ◽

Shawnta Jackson ◽

Haifeng Zhang ◽

...

Keyword(s):

Dose Escalation ◽

Plaque Psoriasis ◽

Janus Kinase ◽

Chronic Plaque Psoriasis ◽

Dose Escalation Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Janus Kinase 1

Download Full-text

A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2008.11.787 ◽

2009 ◽

Vol 60 (3) ◽

pp. AB181

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Phase Iv

Download Full-text

Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2006.10.075 ◽

2007 ◽

Vol 56 (2) ◽

pp. AB6 ◽

Cited By ~ 1

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Preliminary Results

Download Full-text

A double-blind, placebo-controlled, dose escalation safety, and efficacy study of ziac in patients, ages 6–17 years, with hypertension

American Journal of Hypertension ◽

10.1016/s0895-7061(00)00390-3 ◽

2000 ◽

Vol 13 (6) ◽

pp. S38-S39 ◽

Cited By ~ 7

Author(s):

R Cunningham

Keyword(s):

Dose Escalation ◽

Efficacy Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Patients Âgés

Download Full-text

Pharmacokinetics and Safety Profile of Bleselumab (ASKP1240) in Patients With Moderate-To-Severe Plaque Psoriasis: Results from a Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2017.05.208 ◽

2017 ◽

Vol 39 (8) ◽

pp. e68 ◽

Cited By ~ 1

Author(s):

M.S.A. Kumar ◽

R. Tainaka ◽

T. Zhu ◽

X. Wang ◽

J. Montgomery ◽

...

Keyword(s):

Dose Escalation ◽

Plaque Psoriasis ◽

Safety Profile ◽

Multiple Dose ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2007.10.044 ◽

2008 ◽

Vol 58 (2) ◽

pp. AB4

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Global Evaluation ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1016127.204243 ◽

2004 ◽

Author(s):

Guoping Feng

Keyword(s):

Multiple Sclerosis ◽

Phospholipase A2 ◽

Cytosolic Phospholipase A2 ◽

Cytosolic Phospholipase

Download Full-text

Faculty Opinions recommendation of Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160853.622273 ◽

2009 ◽

Author(s):

Davide Pareyson ◽

Chiara Marchesi

Keyword(s):

Ascorbic Acid ◽

Disease Type ◽

Efficacy Trial ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Charcot Marie Tooth ◽

Charcot Marie Tooth Disease ◽

Tooth Disease

Download Full-text

Faculty Opinions recommendation of A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162202.622674 ◽

2009 ◽

Author(s):

Michael O'Connor

Keyword(s):

Acute Respiratory Distress Syndrome ◽

Acute Lung Injury ◽

Lung Injury ◽

Active Site ◽

Distress Syndrome ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text